A single-blinded phase II clinical trial compared the effects of GP2+GM-CSF versus GM-CSF alone in high-risk, human leukocyte antigen (HLA)-A2/A3-positive BC patients who were disease-free following standard therapy. The gene discussed is CSF2; the disease is breast cancer.